HTGMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (15 6月 2023 @ 05:00):

Stats
本日の出来高	725 429
平均出来高	253 915
時価総額	1.06M
EPS	$0 ( 2024-03-28 )
次の収益日	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0281
ATR14	$0.314 (65.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-08	Barat Stephen	Sell	888	Common Stock
2023-03-31	Barat Stephen	Sell	52	Common Stock
2023-02-02	Barat Stephen	Sell	0	Common Stock
2023-02-02	Barat Stephen	Sell	4 166	Stock Option (right to buy)
2023-02-02	Barat Stephen	Sell	2 083	Stock Option (right to buy)

INSIDER POWER
93.68
Last 98 transactions
Buy: 3 245 171 \| Sell: 16 674

ボリューム相関

長: 0.10 (neutral)

短: -0.53 (weak negative)

Signal:(18.674) Neutral

HTG Molecular Diagnostics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

HTG Molecular Diagnostics 相関 - 通貨/商品

0.64
( weak )

0.73
( moderate )

0.00
( neutral )

0.75
( moderate )

-0.12
( neutral )

-0.75
( moderate negative )

HTG Molecular Diagnostics 財務諸表

Annual	2022
収益:	$6.37M
総利益:	$1.79M (28.18 %)
EPS:	$-24.28

FY	2022
収益:	$6.37M
総利益:	$1.79M (28.18 %)
EPS:	$-24.28

FY	2021
収益:	$8.91M
総利益:	$716 868 (8.05 %)
EPS:	$-0.206

FY	2020
収益:	$8.55M
総利益:	$4.56M (53.31 %)
EPS:	$-0.376

Financial Reports:

No articles found.

HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.